- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02792556
Urine Pregnancy Test Compared to Transvaginal Ultrasound (CHECK-TOP). (CHECK-TOP)
Evaluation of Urine Pregnancy Test, CHECK TOP Test, Compared to Transvaginal Ultrasound During Control Visit Post Drug Abortion (CHECK-TOP).
According to a study of the DREES (Direction de la Recherche, des Etudes, de l'Evaluation et des Statistiques), in 2013, nearly 229 000 abortions were performed in France, an increasing number.
The success rate of drug abortion before 49 days of amenorrhea, defined by the National Health Autority as a complete abortion not requiring surgery, varies from 92 to 98% depending on the pregnancy term and the dose used.
The control visit is performed between the 14th day and the 21th day post abortion. Its role is to monitor the effectiveness of the method, to verify absence of complication and to better adapt contraception to prevent another unwanted pregnancy. The choice of the method is left to the physician's discretion: β-HCG dosage, pelvic or transvaginal ultrasound.
In the Orthogenic Departement of the Croix-Rousse Hospital Lyon, France, the method performed during the control visit is transvaginal ultrasound.
To simplify the monitoring of drug abortion, a urine pregnancy test would be an attractive alternative to transvaginal ultrasound: simplicity of use, speed, ease of interpretation and low cost.
The main objective of this study is to evaluate the diagnostic value of urine pregnancy test CHECK TOP compared to transvaginal ultrasound in monitoring the outcome of drug abortion during the control visit.
This is a monocentric observational study.
Study Overview
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Corine REBELLE, MD
- Phone Number: +33 4 72 07 16 63
- Email: corine.rebelle@chu-lyon.fr
Study Contact Backup
- Name: Mahé RAFFIN
- Phone Number: +33 4.26.73.27.38
- Email: mahe.raffin@chu-lyon.fr
Study Locations
-
-
-
Lyon, France, 69004
- Recruiting
- Hospices Civils de Lyon - Hopital de la Croix Rousse
-
Contact:
- Corinne REBELLE
- Phone Number: +33 4 72 07 16 63
- Email: corine.rebelle@chu-lyon.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Women ≥18 years of age
- Undergoing drug abortion in Orthogenic Departement, Croix-Rousse Hospital, Lyon
- Intrauterine pregnancy, single or multiple, until 8 weeks of amenorrhea
- Agreeing to participate in the study after receiving information note
- Affiliated to a social security system
- Not subject to a measure of legal protection
Exclusion Criteria:
- Women <18 years
- Ineligible patient to drug abortion
- Patient practicing a surgical abortion
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
patient having a drug abortion
Urine pregnancy test for adult women having a drug abortion until 8 weeks of amenorrhea, presenting to the control visit between the 14th and 21th day after drug intake.
|
Urine pregnancy test Check Top after transvaginal ultrasound
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Negative predictive value of urine pregnancy test CHECK TOP
Time Frame: During control visit post drug abortion, after transvaginal ultrasound (at day14 or day21)
|
Negative predictive value of urine pregnancy test CHECK TOP taking as reference transvaginal ultrasound. A negative result at transvaginal ultrasound will be defined as the absence of ongoing pregnancy. An ongoing pregnancy is characterized by the presence of gestational sac, yolk sac and/or embryo with cardiac activity. A positive result will be retained only in case of ongoing pregnancy. Check Top test will be considered as negative if only one colored line appears in the control window, without any line in the result window. It will be considered as positive if two colored lines are present in the result window, corresponding to a β-HCG level > 1000 IU/ml. |
During control visit post drug abortion, after transvaginal ultrasound (at day14 or day21)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Positive predictive value of urine pregnancy test Check Top
Time Frame: During control visit post drug abortion, after transvaginal ultrasound (at day14 or day21)
|
Positive predictive value of urine pregnancy test Check Top compared to transvaginal ultrasound.
|
During control visit post drug abortion, after transvaginal ultrasound (at day14 or day21)
|
Sensibility of urine pregnancy test Check Top
Time Frame: During control visit post drug abortion, after transvaginal ultrasound (at day14 or day21)
|
Sensibility of urine pregnancy test Check Top compared to transvaginal ultrasound.
|
During control visit post drug abortion, after transvaginal ultrasound (at day14 or day21)
|
Specificity of urine pregnancy test Check Top
Time Frame: During control visit post drug abortion, after transvaginal ultrasound (at day14 or day21)
|
Specificity of urine pregnancy test Check Top compared to transvaginal ultrasound.
|
During control visit post drug abortion, after transvaginal ultrasound (at day14 or day21)
|
Acceptability of urine pregnancy test Check Top by patients.
Time Frame: During control visit post drug abortion, after transvaginal ultrasound (at day14 or day21)
|
Questionnaire
|
During control visit post drug abortion, after transvaginal ultrasound (at day14 or day21)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 69HCL16_0263
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Abortion
-
Marie Stopes InternationalUnknownPharmacies | Abortion, Drug-Induced
-
Ataturk UniversityCompletedOxytocin Infusion vs. Spontaneous Follow-up for Third-stage of Labor After Second-trimester AbortionAbortion, Induced | Pregnancy Trimester, Second | Labor Stage, Third/Drug Effects | Oxytocin/Administration & DosageTurkey
-
Centre Hospitalier Universitaire, AmiensWithdrawnMisoprostol | Drug-induced AbortionFrance
-
IpasSt. Paul's Hospital Millennium Medical College, Addis Ababa, EthiopiaCompletedMedical Abortion | Induced Abortion | Second Trimester Abortion | Health PersonnelEthiopia
-
Marie Stopes InternationalLondon School of Hygiene and Tropical Medicine; IpasCompletedContraception | Abortion | Post-abortionBangladesh
-
National University of MalaysiaRecruitingMedical; Abortion, Fetus | Missed Abortion | Incomplete AbortionMalaysia
-
IpasUnknownInduced Abortion | First Trimester AbortionNigeria
-
Central Hospital, Nancy, FranceCompletedAbortion in First Trimester | Abortion, Second Trimester
-
Boston UniversityCompletedAbortion, Induced | Abortion, Second TrimesterUnited States
-
Boston UniversityCompletedAbortion, Induced | Abortion, Second TrimesterUnited States
Clinical Trials on Urine pregnancy test
-
Gynuity Health ProjectsStanford UniversityCompletedEmbryo Transfer | Intrauterine Insemination (IUI)United States
-
St George's, University of LondonUnknownGroup B StreptococcusUnited Kingdom
-
Planned Parenthood League of MassachusettsSociety of Family PlanningCompletedFollow-up After Uterine EvacuationUnited States
-
Gynuity Health ProjectsCompletedMenstrual RegulationPakistan
-
Mayo ClinicRecruiting
-
Gynuity Health ProjectsCompleted
-
Guangzhou Wondfo Biotech Co., LtdNova Clinical Solutions, Inc.CompletedPregnancyUnited States
-
University of Cape TownKarolinska InstitutetCompletedCompletion of Medical AbortionSouth Africa
-
Indiana UniversityMoi UniversityCompletedContraceptive Usage | Prenatal Care Late | Pregnancy ComplicationKenya
-
Gynuity Health ProjectsCompletedMedical AbortionVietnam